Zymeworks Inc.
ZYME- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937653
No open-market purchases or sales by Zymeworks Inc. insiders were filed in the last 90 days; 202 institutions reported holding it in 13F filings for Q2 2026, worth $1.79B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Zymeworks Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +6 vs. Q3 2022
- Shares held
- 57.2M
- +9.76M (+20.6%) vs. Q3 2022
- Total value
- $449.9M
- +$157.9M (+54.1%) vs. Q3 2022
- New holders
- 33
- 31 more added
- Sold out
- 27
- 17 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZYME on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 202 | $1.79B |
| Q1 2026 | 212 | $1.76B |
| Q4 2025 | 210 | $1.88B |
| Q3 2025 | 184 | $1.26B |
| Q2 2025 | 182 | $949.0M |
| Q1 2025 | 186 | $840.9M |
| Q4 2024 | 174 | $973.2M |
| Q3 2024 | 163 | $834.7M |
| Q2 2024 | 164 | $580.6M |
| Q1 2024 | 171 | $713.0M |
| Q4 2023 | 157 | $674.0M |
| Q3 2023 | 140 | $395.5M |
| Q2 2023 | 137 | $547.9M |
| Q1 2023 | 116 | $512.6M |
| Q4 2022 | 96 | $449.9M |
| Q3 2022 | 91 | $293.7M |
| Q2 2022 | 114 | $253.3M |
| Q1 2022 | 120 | $327.3M |
| Q4 2021 | 114 | $693.9M |
| Q3 2021 | 123 | $1.07B |
| Q2 2021 | 109 | $1.20B |
| Q1 2021 | 125 | $1.12B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Zymeworks Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Quinn Opportunity Partners LLC | 0 | $0 | 0.00% | −456,822−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −395,478−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −291,000−100.0% | Sold out |
| Velan Capital Investment Management LP | 0 | $0 | 0.00% | −234,902−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −215,000−100.0% | Sold out |
| Clearline Capital LP | 0 | $0 | 0.00% | −193,288−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −158,066−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −93,824−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −59,457−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −46,683−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −36,572−100.0% | Sold out |
| Marathon Capital Management | 0 | $0 | 0.00% | −27,250−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −25,374−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −24,583−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −23,768−100.0% | Sold out |
| Guggenheim Capital LLC | 0 | $0 | 0.00% | −18,831−100.0% | Sold out |
| Values First Advisors, Inc. | 0 | $0 | 0.00% | −16,998−100.0% | Sold out |
| Wela Strategies, Inc. | 0 | $0 | 0.00% | −14,796−100.0% | Sold out |
| Firethorn Wealth Partners, LLC | 0 | $0 | 0.00% | −11,800−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −11,079−100.0% | Sold out |
| Public Employees Retirement Association of Colorado | 0 | $0 | 0.00% | −7,991−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −1,117−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −178−100.0% | Sold out |
| Strategic Wealth Advisors Group, LLC | – | – | – | – | Not filed |